Document kmkygNddaVbBrZqeQyDwzgwdE

~ E r t s ~ 565 310 400 400 ( [ E F E 198 180 180 ( / E ( F30 63 ~ 30 E r e I / l- e E t e r E I- 1113 950 400 400 e r c i e s LO includes about $ 200 K per year for butadiene research and advocacy, and the Aromatics value is heavily weighted with the Shanghai study. HPV testing also contributes significantly to the budgets for most of the PBUs. 2006 still has some uncertainty, but will possibly include the initiation of the long awaited US EPA endocrine screening program, and a possible global product management program in the US (possibly the US answer to REACH). The value to the PBUs are in the following areas: 1. Meeting commitments (eg., HPV and VCCEP) 2. Advocacy to protect license to operate (butadiene and the Clean Air Act, as we discussed, is a good example) 3. Protection of reputation as per Responsible Care and Product Stewardship. SHELL-MCCLURG-059612